Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer

Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer

Abstract Objective CD47 is an antiphagocytic molecule that contributes to tumor cell resistance in host immune surveillance. CD47 overexpression correlated with tumor progression and shorter survival in lung cancer. However, the expression and functional significance of CD47 in Non‐Small Cell Lung C...

Full description

Bibliographic Details
Main Authors:	Oscar Arrieta, Alejandro Aviles‐Salas, Mario Orozco‐Morales, Norma Hernández‐Pedro, Andrés F. Cardona, Luis Cabrera‐Miranda, Pedro Barrios‐Bernal, Giovanny Soca‐Chafre, Graciela Cruz‐Rico, María de Lourdes Peña‐Torres, Guadalupe Moncada‐Claudio, Laura‐Alejandra Ramirez‐Tirado
Format:	Article
Language:	English
Published:	Wiley 2020-04-01
Series:	Cancer Medicine
Subjects:	CD47 EGFR immune checkpoint lung adenocarcinoma phagocytosis
Online Access:	https://doi.org/10.1002/cam4.2882

Similar Items

Acute CD47 Blockade During Ischemic Myocardial Reperfusion Enhances Phagocytosis-Associated Cardiac Repair
by: Shuang Zhang, BS, et al.
Published: (2017-08-01)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
by: Yan Yang, et al.
Published: (2021-07-01)

Harnessing Macrophages through the Blockage of CD47: Implications for Acute Myeloid Leukemia
by: Luciana Melo Garcia, et al.
Published: (2021-12-01)

Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?
by: Renee Bouwstra, et al.
Published: (2019-05-01)

A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer
by: Fangzhen Lin, et al.
Published: (2021-01-01)

Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade
by: Abdullahi Alausa, et al.
Published: (2022-07-01)

Targeting CD47 as a therapeutic strategy: A common bridge in the therapy of COVID-19-related cancers
by: Milad Zandi, et al.
Published: (2023-07-01)

Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile
by: Tao Wang, et al.
Published: (2024-03-01)

A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells
by: Youg R. Thaker, et al.
Published: (2022-05-01)

Targeting HDAC6 improves anti-CD47 immunotherapy
by: Maria Gracia-Hernandez, et al.
Published: (2024-02-01)

CD47–SIRPα-targeted therapeutics: status and prospects
by: R. Maute, et al.
Published: (2022-03-01)

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
by: Wenting Zhang, et al.
Published: (2020-01-01)

Construction of Exosomes that Overexpress CD47 and Evaluation of Their Immune Escape
by: Xin-Yu Ben, et al.
Published: (2022-06-01)

Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity
by: Tracy C. Kuo, et al.
Published: (2020-11-01)

Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation
by: Zhiqiang Li, et al.
Published: (2021-08-01)

Characterization of the Pathophysiological Role of CD47 in Uveal Melanoma
by: Maria Cristina Petralia, et al.
Published: (2019-07-01)

Antibody:CD47 ratio regulates macrophage phagocytosis through competitive receptor phosphorylation
by: Emily C. Suter, et al.
Published: (2021-08-01)

CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT
by: Muhammad Zaeem Noman, et al.
Published: (2018-04-01)

Tolerating CD47
by: Jeffrey S. Isenberg, et al.
Published: (2024-02-01)

Structural–functional diversity of CD47 proteoforms
by: Ting Zhang, et al.
Published: (2024-02-01)

Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
by: Tailong Qu, et al.
Published: (2022-04-01)

Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC
by: Annunziata Nigro, et al.
Published: (2020-01-01)

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma
by: Dan Zhu, et al.
Published: (2024-12-01)

Anomalous Levels of CD47/Signal Regulatory Protein Alpha in the Hippocampus Lead to Excess Microglial Engulfment in Mouse Model of Perioperative Neurocognitive Disorders
by: Min Shui, et al.
Published: (2022-03-01)

YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells
by: Anna Josefine von Ofen, et al.
Published: (2024-01-01)

CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies
by: Jennifer Sun, et al.
Published: (2021-01-01)

CD47 blockade enhances phagocytosis of cardiac cell debris by neutrophils
by: Elias Haj-Yehia, et al.
Published: (2023-10-01)

Correlation of CD47 Expression with Adverse Clinicopathologic Features and an Unfavorable Prognosis in Colorectal Adenocarcinoma
by: Hyunsung Kim, et al.
Published: (2021-04-01)

Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer
by: ZHA Li, et al.
Published: (2018-08-01)

RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47Sc-conjugated cetuximab
by: Da-Mi Kim, et al.
Published: (2023-07-01)

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages
by: Tobias Zeller, et al.
Published: (2022-10-01)

Targeting CD47 as a Novel Immunotherapy for Breast Cancer
by: Can Chen, et al.
Published: (2022-07-01)

Regulation of CD47 expression on CD14+ monocytes by interferon-α in PBC patients
by: Xi Su, et al.
Published: (2023-12-01)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
by: Siret Tahk, et al.
Published: (2021-09-01)

Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition
by: Michal Caspi Tal, et al.
Published: (2020-06-01)

EGFR of platelet regulates macrophage activation and bacterial phagocytosis function
by: Shuhua Luo, et al.
Published: (2024-04-01)

Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
by: Leonie M. Behrens, et al.
Published: (2022-07-01)

Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo
by: Zu-Chian Chiang, et al.
Published: (2022-05-01)

CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies
by: Jason C. Andrechak, et al.
Published: (2022-04-01)

CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
by: Asa P. Y. Lau, et al.
Published: (2023-10-01)